Osma FSJ, Morales CM, Navarro MVR, Moreno SOE, Curbelo LM, Carles FTH

Language: Spanish
References: 16
Page: 1-12
PDF size: 379.01 Kb.

ABSTRACT

Introduction: In Panama, temporary centers for medical care were created in some public establishments to meet the massive demand for cases with COVID-19.
Objective: To clinically describe hospitalized patients with moderate COVID-19. Methods: A descriptive, ambispective, case series study was conducted from February to April 2021. It included all admissions in the first 5 months of the Comprehensive Care Center for Moderate Cases due to COVID-19 in Figali. A questionnaire was designed for each patient with data collected from individual electronic medical records.
Results: Out of 628 admitted patients, 58.1% were men and 41.6% were in the age group ≥60 years. 54.94% were admitted after 7 days of symptoms, mainly from isolation hotels (39.65%) and hospitals (26.43%). The most frequent symptoms were cough, dyspnea, fever and weakness. 84.39% were classified as moderate COVID-19. 51.75% required admission to the Special Respiratory Care Unit, and out of these 3.82% required invasive mechanical ventilation. 67.70% were discharged and 14.59% were transferred to third level hospitals after orotracheal intubation.
Conclusions: Centro Figali provided medical care to patients with moderate, severe and critical COVID-19. General and upper respiratory symptoms prevailed, which intensified in the pulmonary phase of the disease and led to admission. Among men, older adults and patients with chronic non-communicable diseases were the majority of those admitted and deceased.

REFERENCES

1. Organización Panamericana de la Salud, Organización Mundial de la Salud. Reporte de Situación COVID-19 Panamá. Reporte No. 52 Abril 20 de 2021. Washington, D.C.: OPS/OMS; 2021[acceso: 29/04/2021]. Disponible en: https://www.paho.org/es/documentos/covid-19-informe-situacion-panama-ndeg52-abril-20-2021

2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;30;382(18):1708-20. DOI: https://doi.org/10.1056/NEJMoa2002032

3. Organización Panamericana de la Salud, Organización Mundial de la Salud. Actualización epidemiológica: Enfermedad por Coronavirus (COVID-19). 14 de abril de 2021, Washington, D.C.: OPS/OMS. 2021[acceso: 29/04/2021]. Disponible en: https://www.paho.org/es/documentos/actualizacion-epidemiologica-enfermedad-por-coronavirus-covid-19-14-abril-2021

4. Ge H, Wang X, Wuan X, Yuan X, Xiao G, Wang C, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020;39:1011-19. DOI: https://doi.org/10.1007/s10096-020-03874-z

5. Saldías F, Peñaloza A, Farías D, Farcas K, Reyes A, Cortés J, et al. Manifestaciones clínicas y predictores de gravedad en pacientes adultos con infección respiratoria aguda por coronavirus SARS-CoV-2. RevMed Chile. 2020;148(10):1387-97. DOI: http://dx.doi.org/10.4067/S0034-98872020001001387

6. Marín Sánchez A. Características clínicas básicas en los primeros 100 casos fatales de COVID-19 en Colombia. Rev Panam Salud Pública. 2020;44:e87. DOI: https://doi.org/10.26633/RPSP.2020.87

7. León Álvarez JL, Calderón Martínez M, Gutiérrez Rojas AR. Análisis de mortalidad y comorbilidad por COVID-19 en Cuba. Rev Cub Med. 2021 [acceso: 26/04/2021];60(2). Disponible en: http://www.revmedicina.sld.cu/index.php/med/article/view/2117

8. Ministerio de Salud. República de Panamá. Recomendaciones de atención de pacientes COVID-19 hospitalizados. 4th ed. MINSA: Cuidad Panamá. 2020[acceso: 01/03/2020]. Disponible en: http://minsa.b-cdn.net/sites/default/files/publicacion-general/recomendaciones_manejo_covid-19_version_4.0_9_de_abril_revisado_digesa_def14_abrildef_0.pdf

9. Zuccone G, Albornoz V, Ibáñez H, Betancur R, Matute J. Características clínicas y epidemiológicas del COVID-19 en la Unidad de Emergencia del Hospital Barros Luco: los primeros 164 pacientes. Rev Med Chile. 2020[acceso: 09/04/2021];148(8):1096-104. Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000801096

10. Villagrán KA, Torrontegui LA, Entzana A. Características clínico-epidemiológicas de pacientes de COVID-19 en un Hospital de Sinaloa, México. Rev Med UAS. 2020[acceso: 29/04/2021];10(2):65-79. Disponible en: http://hospital.uas.edu.mx/revmeduas/articulos/v10/n2/covit19hcc.pdf

11. Hannawi S, Hannawi H, Naeem KB, Elemam NM, Hachim MY, Hachim IY, et al. Clinical and laboratory profile of hospitalized symptomatic COVID-19 patients: case series study from the first COVID-19 Center in the UAE. Front Cell Infect Microbiol. 2021;11(732965):1-10. DOI: https://doi.org/10.3389/fcimb.2021.632965

12. Dos Santos. WG. Natural history of COVID-19 and current knowledge on treatment therapeutic options. Biomed Pharmacother. 2020;129:110493. DOI: https://doi.org/10.1016/j.biopha.2020.110493

13. Sinha P, Matthay MA, Calfee CS. Is a "Cytokine Storm" Relevant to COVID-19? JAMA Intern Med. 2020;180(9):1152-54. DOI: https://doi.org/10.1001/jamainternmed.2020.3313

14. Seidu S, Gillies C, Zaccardi F, Kunutsor SK, Hartmann-Boyce J, Yates T, et al. The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis. Endocrinol Diab Metab. 2020;00:e00176. DOI: https://doi.org/10.1002/edm2.176

15. Sheppard JP, Nicholson BD, Lee J, McGagh D, Sherlock J, Koshiaris C, et al. Association between blood pressure control and coronavirus disease 2019 outcomes in 45 418 symptomatic patients with hypertension: an observational cohort study. Hypertension. 2021;77(3):846-55. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.120.16472

16. Lima MM, Carrera C, Madera Silva MD, Marín W, Contreras M. COVID-19 y diabetes mellitus: una relación bidireccional. Clin Investig Arterioscler. 2020;(20)30105-4. DOI: https://doi.org/10.1016/j.arteri.2020.10.001